Repurposing of Triazole Drugs to Combat Common Cancer Cases

Sevilay Cengiz; Berna Kavakcıoğlu Yardımcı

Makale detayları

Repurposing of Triazole Drugs to Combat Common Cancer Cases

Yazarlar:

Sevilay Cengiz | Berna Kavakcıoğlu Yardımcı

Yayıncı:

Duzce University

Ana Başlıklar:

Mühendislik

Dergi:

Düzce Üniversitesi Bilim ve Teknoloji Dergisi Vol.11 Issue 1, pp.276-287

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282905

pISSN:

2148-2446

Anahtar kelimeler:

Özet:

 Cancer with its prevalence and high mortality rates is an important problem that health authorities are trying to deal with all over the world. According to the data of the International Agency for Research on Cancer, 19.3 million new cancer cases occurred worldwide in 2020, and unfortunately, about 10 million of them resulted in death. The discovery of new drugs is compulsory due to restrictions such as the side effects of currently used anti-cancer drugs, drug resistance developing over time, and so on. Unfortunately the development of novel drugs requires especially a long time and a huge amount of cost. At this point, the repurposing approach, which refers to the secondary use of various drugs that was approved by FDA for other purposes, has a vital importance. In this study, the anti-proliferative effects of ICZ and FCZ, which are actually antifungal drugs, on breast MCF-7 and MDA-MB-231 and lung A549 cancer cells were evaluated. Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.

 Cancer with its prevalence and high mortality rates is an important problem that health authorities are trying to deal with all over the world. According to the data of the International Agency for Research on Cancer, 19.3 million new cancer cases occurred worldwide in 2020, and unfortunately, about 10 million of them resulted in death. The discovery of new drugs is compulsory due to restrictions such as the side effects of currently used anti-cancer drugs, drug resistance developing over time, and so on. Unfortunately the development of novel drugs requires especially a long time and a huge amount of cost. At this point, the repurposing approach, which refers to the secondary use of various drugs that was approved by FDA for other purposes, has a vital importance. In this study, the anti-proliferative effects of ICZ and FCZ, which are actually antifungal drugs, on breast MCF-7 and MDA-MB-231 and lung A549 cancer cells were evaluated. Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.

 Cancer with its prevalence and high mortality rates is an important problem that health authorities are trying to deal with all over the world. According to the data of the International Agency for Research on Cancer, 19.3 million new cancer cases occurred worldwide in 2020, and unfortunately, about 10 million of them resulted in death. The discovery of new drugs is compulsory due to restrictions such as the side effects of currently used anti-cancer drugs, drug resistance developing over time, and so on. Unfortunately the development of novel drugs requires especially a long time and a huge amount of cost. At this point, the repurposing approach, which refers to the secondary use of various drugs that was approved by FDA for other purposes, has a vital importance. In this study, the anti-proliferative effects of ICZ and FCZ, which are actually antifungal drugs, on breast MCF-7 and MDA-MB-231 and lung A549 cancer cells were evaluated. Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.

 Yaygınlığı ve yüksek ölüm oranları ile kanser, tüm dünyada sağlık otoritelerinin başa çıkmaya çalıştığı önemli bir sorundur. Uluslararası Kanser Araştırmaları Ajansının verilerine göre 2020 yılında dünya genelinde 19.3 milyon yeni kanser vakası meydana gelmiş ve ne yazık ki, bunların yaklaşık 10 milyonu ölümle sonuçlanmıştır. Halihazırda kullanılan anti-kanser ilaçlarının yan etkileri, zamanla gelişen ilaç direnci vb. kısıtlamalar nedeniyle yeni ilaçların keşfi zorunludur. Ne yazık ki, yeni ilaçların geliştirilmesi özellikle uzun bir zaman ve büyük bir maliyet gerektirmektedir. Bu noktada FDA tarafından farklı amaçlarla onaylanan çeşitli ilaçların başka amaçlarla sekonder kullanımını ifade eden yeniden kullanım yaklaşımı hayati bir önem taşımaktadır. Bu çalışmada aslında antifungal ilaçlar olan ICZ ve FCZnin meme MCF-7 ve MDA-MB-231 ve akciğer A549 kanser hücreleri üzerindeki antiproliferatif etkileri değerlendirilmiştir. Sonuçlar, her iki ilacın da A549 hücre proliferasyonu üzerinde düşük bir inhibitör etkiye sahip olduğunu, buna karşın MCF-7 ve MDA-MB-231 hücre proliferasyonu üzerinde umut verici bir inhibisyona neden olduklarını ortaya koymuştur.

Makale detayları

Repurposing of Triazole Drugs to Combat Common Cancer Cases

Yazarlar:

Sevilay Cengiz | Berna Kavakcıoğlu Yardımcı

Yayıncı:

Duzce University

Ana Başlıklar:

Mühendislik

Dergi:

Düzce Üniversitesi Bilim ve Teknoloji Dergisi Vol.11 Issue 1, pp.276-287

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282905

pISSN:

2148-2446

breast cancer

fluconazole

itraconazaole

lung cancer

repurposing

meme kanseri

flukonazol

itrakonazol

akciğer kanseri

yeniden kullanım.

Sayı

Makale detayları

Yazarlar: Sevilay Cengiz | Berna Kavakcıoğlu Yardımcı

Yayıncı: Duzce University

Ana Başlıklar: Mühendislik

Dergi: Düzce Üniversitesi Bilim ve Teknoloji Dergisi Vol.11 Issue 1, pp.276-287

Belge Tipi: Makale

Yayın Tarihi: 1/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001282905

pISSN: 2148-2446

Sayı

Yazarlar:

Sevilay Cengiz | Berna Kavakcıoğlu Yardımcı

Yayıncı:

Duzce University

Ana Başlıklar:

Mühendislik

Dergi:

Düzce Üniversitesi Bilim ve Teknoloji Dergisi Vol.11 Issue 1, pp.276-287

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282905

pISSN:

2148-2446